When I last covered Onyx Pharmaceuticals (NASDAQ:ONXX) on June 19th, the company was trading at a market capitalization of approximately $3 billion dollars ahead of a review of Kyprolis (carfilzomib) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback